India, Nov. 20 -- Friday, Johnson & Johnson (JNJ) announced positive results from its Phase 4 STAR study of TREMFYA (guselkumab) in adults with active psoriatic arthritis (PsA) affecting the spine. The study showed that TREMFYA improved back pain, stiffness and other disease symptoms while reducing inflammation in the joints connecting the lower spine to the pelvis.

Improvement In Pain And Stiffness

After 24 weeks of treatment, patients receiving TREMFYA every four weeks showed a 3.3-point improvement in BASDAI scores, while those receiving it every eight weeks showed a 2.9-point improvement. Patients receiving placebo showed a 2.1-point improvement.

TREMFYA also improved ASDAS-CRP scores, which measure disease activity and inflammation....